Clinical trials
HER2-positive Breast Cancer clinical trials
Below are recruiting her2-positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 242 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05573893Recruiting
Real-world study of trastuzumab deruxtecan for HER2 breast cancer
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
AmbergAges 18–130 - NCT06328465Recruiting
MRI for early detection of breast cancer spread
This trial is testing a new way to use MRI scans to find breast cancer that has spread to other parts of the body early. It is for people who have had aggressive breast cancer (HER2 positive or triple negative) and finished treatment with surgery, but still have a higher risk of the cancer coming back.
MilanAges 18–75 - NCT06348134RecruitingPhase 2
Anti-HER2 Therapy Before and After Surgery for HER2-Positive Breast Cancer
This trial tests a targeted therapy (anti-HER2) given before and after surgery for Nigerian women with HER2-positive breast cancer. It aims to see if this treatment helps shrink tumors and improve outcomes.
Ikeja, LagosAges 18 years+ - NCT06358625Recruiting
Study of brain recurrence risk in HER2-positive breast cancer
This study looks at women with HER2-positive breast cancer who will get chemotherapy before surgery. The goal is to find out what factors might increase the chance of the cancer spreading to the brain later on.
RennesAges 18 years+ - NCT06414733RecruitingPhase 1
HER-2 B Cell Peptide Vaccine for Advanced Cancers
This trial tests a vaccine that helps your immune system attack cancer cells that have HER2 or EGFR proteins. It is for people with advanced breast or gastrointestinal cancer whose disease has worsened after standard treatment.
Indianpolis, IndianaAges 18 years+ - NCT06439693RecruitingPhase 2
Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Boston, MassachusettsAges 18 years+ - NCT06441890RecruitingPhase 2
Personalized chemo before breast cancer surgery
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Chicago, IllinoisAges 18 years+ - NCT06445738Recruiting
Can some women safely skip radiation after breast cancer surgery?
This trial is for women 50 and older with early-stage, hormone-positive or HER2-positive breast cancer. It tests whether it is safe to skip radiation therapy after a lumpectomy if an MRI before surgery shows the breast tissue looks a certain way.
San Francisco, CaliforniaAges 50 years+ - NCT06446882Recruiting
HER2DX test to guide treatment for early HER2+ breast cancer
This trial tests whether a new test (HER2DX) can help doctors choose the best treatment combination for HER2-positive breast cancer before surgery. It's for people whose cancer hasn't spread and who haven't started therapy yet.
GrazAges 18 years+ - NCT06450314RecruitingPhase 2
De-escalating treatment for advanced HER2-positive breast cancer
This trial tests whether it's safe to reduce or stop some cancer treatments for people whose advanced HER2-positive breast cancer has been well-controlled for at least 2 years and has no detectable cancer cells in blood tests.
RennesAges 18 years+ - NCT06479460Recruiting
Blood test monitoring during chemo before surgery for HER2-positive breast cancer
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
Nanjing, JiangsuAges 18–75 - NCT06503783RecruitingPhase 1
Study of BL-M17D1 for advanced breast cancer and solid tumors
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT06517212RecruitingPhase 2
Tirzepatide for weight loss in MRD-positive early breast cancer
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
Dallas, TexasAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Birmingham, AlabamaAges 18 years+ - NCT06589830RecruitingPhase 2
TL938 with Trastuzumab for HER2+ Colorectal Cancer
This trial is testing a new combination of drugs (TL938 and trastuzumab) for people with a specific type of advanced colorectal cancer that is HER2-positive and RAS wild-type. It may offer a new option if you have already tried standard chemotherapy and a blood vessel-blocking drug.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06603597Recruiting
HER2-positive breast cancer registry
This registry tracks people with HER2-positive breast cancer to learn more about the disease and how it's treated. You can join at any stage of cancer.
Overland Park, KansasAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06744465Recruiting
Light-based monitoring for breast cancer during chemo
This study uses a special light-based device to monitor breast cancer during chemotherapy before surgery. It is for women with HER2-positive or triple-negative breast cancer who are planning chemotherapy first.
Indianapolis, IndianaAges 18 years+ - NCT06770296RecruitingPhase 1
Finding the best dose of pyrotinib for first-line advanced HER2 breast cancer
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Nanjing, JiangsuAges 18–75 - NCT06830382Recruiting
HER2-PET scan for metastatic breast cancer treatment
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
SolnaAges 18 years+ - NCT06892093Recruiting
Probiotics to prevent diarrhea from neratinib in breast cancer
This trial tests whether taking probiotics can help prevent diarrhea caused by the breast cancer drug neratinib. If you are a woman with HER2-positive breast cancer and are about to start neratinib, this study may help manage a common side effect.
Guangzhou, GuangdongAges 18 years+ - NCT06904625Recruiting
Capturing tumor cells in metastatic breast or prostate cancer
This study compares different methods of capturing circulating tumor cells (CTCs) from blood samples in patients with metastatic breast or prostate cancer. It aims to improve how we detect and monitor cancer cells that have spread, which could help guide future treatment decisions.
ToulouseAges 18 years+ - NCT06928818Recruiting
T-DM1 after T-DXd for advanced HER2-positive breast cancer
This trial looks at whether a different targeted therapy, T-DM1, can work for women with advanced HER2-positive breast cancer after they have already tried another targeted therapy called T-DXd (Enhertu). If you have progressed while on T-DXd and have not had more than three previous treatments for advanced cancer, you may be able to join.
SeoulAges 19 years+ - NCT06946238Recruiting
Single-dose radiation after surgery for low-risk breast cancer
This trial tests giving a single, very targeted dose of radiation right after surgery for early-stage breast cancer. It is for women age 40+ with small, low-risk tumors (Luminal A or B) that have been fully removed and have not spread to lymph nodes.
MilanAges 40 years+
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-positive breast cancer?
- Yes. Clin2 currently lists 242 recruiting her2-positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HER2-positive Metastatic Breast Cancer
- HER2-positive Advanced Breast Cancer
- HR-positive, HER2-negative Advanced Breast Cancer
- HER2-positive Early Breast Cancer
- HR Positive/HER2 Low Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.